VPA10996/223/001

Ceporex 18 %w/v Suspension for Injection

Variation	Summary	Date
Vet - C9	VNRA - Vet - C9 - - Vet - C9 - Editorial changes to SPC, package leaflet or labelling if inclusion in an upcoming procedure is not possible	16/12/25
Vet - G.I.18	VRA-S - Vet - G.I.18 - - Vet - G.I.18 - One-off alignment of the product information with version 9.0* of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products authorised in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	23/10/25
Vet - F.II.d.1 a)	VRA-S - Vet - F.II.d.1 a) - a) Change outside the approved specifications limits range - F.II.d.1 a) Quality Changes - Finished Product -Control of finished product - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range	12/01/24
Vet - F.II.b.2 b) z.	VRA-R - Vet - F.II.b.2 b) z. - b) Replacement or addition of a manufacturer responsible for importation and/or batch release z. Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.2 b) z. Quality Changes - Finished Product -Manufacture - Change to importer, batch release arrangements and quality control testing of the finished product - Replacement or addition of a manufacturer responsible for importation and/or batch release - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	12/01/24
Vet - F.II.b.1 a)	VRA-S - Vet - F.II.b.1 a) - a) Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/immunological veterinary medicinal products, or for pharmaceutical forms manufactured by complex manufacturing processes - F.II.b.1 a) Quality Changes - Finished Product -Manufacture - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/immunological veterinary medicinal products, or for pharmaceutical forms manufactured by complex manufacturing processes	12/01/24
Vet - B22	VNRA - Vet - B22 - Change to importer, batch control arrangements and quality testing (replacement or addition of a site) for a finished product - B22 Changes to the quality part of the dossier: Change to importer, batch control arrangements and quality testing (replacement or addition of a site) for a finished product	20/10/23
Vet - F.I.f.1	VRA-S - Vet - F.I.f.1 - 1. Substantial changes in the updated	25/05/23

	version of the ASMF or the active substance part of the dossier - F.I.f.1 Quality Changes - Active Substance - Other changes to the active substance - Substantial changes in the updated version of the ASMF or the active substance part of the dossier	
Vet - B30 c)	VNRA - Vet - B30 c) - c) Addition of a new specification parameter to the specification with its corresponding test method - B30 c) Changes to the quality part of the dossier: Change in the specification parameters or limits of the finished product: —addition of a new specification parameter to the specification with its corresponding test method	10/05/23